Nalaganje...
Profile of suvorexant in the management of insomnia
Suvorexant, approved in late 2014 in the United States and Japan for the treatment of insomnia characterized by difficulty achieving and/or maintaining sleep, is a dual orexin receptor antagonist and the first drug in its class to reach the market. Its development followed from the 1998 discovery of...
Shranjeno v:
| izdano v: | Drug Des Devel Ther |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4651361/ https://ncbi.nlm.nih.gov/pubmed/26648692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S73224 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|